Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

E6AP Promotes a Metastatic Phenotype in Prostate Cancer.

Gamell C, Bandilovska I, Gulati T, Kogan A, Lim SC, Kovacevic Z, Takano EA, Timpone C, Agupitan AD, Litchfield C, Blandino G, Horvath LG, Fox SB, Williams SG, Russo A, Gallo E, Paul PJ, Mitchell C, Sandhu S, Keam SP, Haupt S, Richardson DR, Haupt Y.

iScience. 2019 Nov 2;22:1-15. doi: 10.1016/j.isci.2019.10.065. [Epub ahead of print]

2.

p53 nuclear accumulation as an early indicator of lethal prostate cancer.

Quinn DI, Stricker PD, Kench JG, Grogan J, Haynes AM, Henshall SM, Grygiel JJ, Delprado W, Turner JJ, Horvath LG, Mahon KL.

Br J Cancer. 2019 Oct;121(7):578-583. doi: 10.1038/s41416-019-0549-8. Epub 2019 Aug 14.

PMID:
31409910
3.

Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients.

Timmins HC, Li T, Kiernan MC, Horvath LG, Goldstein D, Park SB.

J Pain. 2019 Jul 17. pii: S1526-5900(19)30765-5. doi: 10.1016/j.jpain.2019.06.011. [Epub ahead of print] Review.

PMID:
31325646
4.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

PMID:
31157964
5.

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.

Kwan EM, Fettke H, Docanto MM, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Mangiola S, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhöfer T, Horvath LG, Azad AA.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30139-7. doi: 10.1016/j.euf.2019.04.020. [Epub ahead of print]

PMID:
31103601
6.

Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target.

Lee RS, Zhang L, Berger A, Lawrence MG, Song J, Niranjan B, Davies RG, Lister NL, Sandhu SK, Rubin MA, Risbridger GP, Taylor RA, Rickman DS, Horvath LG, Daly RJ.

Neoplasia. 2019 Apr;21(4):389-400. doi: 10.1016/j.neo.2019.02.005. Epub 2019 Mar 20.

7.

Statins - No more cream for cancer.

Gillessen S, Horvath LG.

Eur J Cancer. 2019 May;112:107-108. doi: 10.1016/j.ejca.2019.02.008. Epub 2019 Mar 16. No abstract available.

PMID:
30885565
8.

Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.

Balaban S, Nassar ZD, Zhang AY, Hosseini-Beheshti E, Centenera MM, Schreuder M, Lin HM, Aishah A, Varney B, Liu-Fu F, Lee LS, Nagarajan SR, Shearer RF, Hardie RA, Raftopulos NL, Kakani MS, Saunders DN, Holst J, Horvath LG, Butler LM, Hoy AJ.

Mol Cancer Res. 2019 Apr;17(4):949-962. doi: 10.1158/1541-7786.MCR-18-0347. Epub 2019 Jan 15.

PMID:
30647103
9.

Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.

Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG.

Eur Urol. 2019 Sep;76(3):306-312. doi: 10.1016/j.eururo.2018.11.001. Epub 2018 Nov 19.

PMID:
30466891
10.

An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.

Zhang AY, Chiam K, Haupt Y, Fox S, Birch S, Tilley W, Butler LM, Knudsen K, Comstock C, Rasiah K, Grogan J, Mahon KL, Bianco-Miotto T, Ricciardelli C, Böhm M, Henshall S, Delprado W, Stricker P, Horvath LG, Kench JG.

Int J Cancer. 2019 Mar 1;144(5):1151-1159. doi: 10.1002/ijc.31906. Epub 2018 Dec 4.

PMID:
30288742
11.

A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis.

Vafaee F, Diakos C, Kirschner MB, Reid G, Michael MZ, Horvath LG, Alinejad-Rokny H, Cheng ZJ, Kuncic Z, Clarke S.

NPJ Syst Biol Appl. 2018 Jun 1;4:20. doi: 10.1038/s41540-018-0056-1. eCollection 2018.

12.

Guidelines for whole genome bisulphite sequencing of intact and FFPET DNA on the Illumina HiSeq X Ten.

Nair SS, Luu PL, Qu W, Maddugoda M, Huschtscha L, Reddel R, Chenevix-Trench G, Toso M, Kench JG, Horvath LG, Hayes VM, Stricker PD, Hughes TP, White DL, Rasko JEJ, Wong JJ, Clark SJ.

Epigenetics Chromatin. 2018 May 28;11(1):24. doi: 10.1186/s13072-018-0194-0.

13.

MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer.

Lin HM, Nikolic I, Yang J, Castillo L, Deng N, Chan CL, Yeung NK, Dodson E, Elsworth B, Spielman C, Lee BY, Boyer Z, Simpson KJ, Daly RJ, Horvath LG, Swarbrick A.

Sci Rep. 2018 May 18;8(1):7820. doi: 10.1038/s41598-018-26050-y.

14.

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.

Roohullah A, Cooper A, Lomax AJ, Aung J, Barge A, Chow L, McHale M, Desai J, Whittle JR, Tran B, de Souza P, Horvath LG.

Invest New Drugs. 2018 Oct;36(5):886-894. doi: 10.1007/s10637-018-0588-7. Epub 2018 May 16.

PMID:
29766337
15.

Enduring epigenetic landmarks define the cancer microenvironment.

Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, Chabanon RM, Qu W, Wang H, Richards M, Nair SS, Armstrong NJ, Nim HT, Papargiris M, Balanathan P, French H, Peters T, Norden S, Ryan A, Pedersen J, Kench J, Daly RJ, Horvath LG, Stricker P, Frydenberg M, Taylor RA, Stirzaker C, Risbridger GP, Clark SJ.

Genome Res. 2018 May;28(5):625-638. doi: 10.1101/gr.229070.117. Epub 2018 Apr 12.

16.

Identification of Novel Response and Predictive Biomarkers to Hsp90 Inhibitors Through Proteomic Profiling of Patient-derived Prostate Tumor Explants.

Nguyen EV, Centenera MM, Moldovan M, Das R, Irani S, Vincent AD, Chan H, Horvath LG, Lynn DJ, Daly RJ, Butler LM.

Mol Cell Proteomics. 2018 Aug;17(8):1470-1486. doi: 10.1074/mcp.RA118.000633. Epub 2018 Apr 9.

17.

Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.

Lin HM, Lee BY, Castillo L, Spielman C, Grogan J, Yeung NK, Kench JG, Stricker PD, Haynes AM, Centenera MM, Butler LM, Shreeve SM, Horvath LG, Daly RJ.

Prostate. 2018 Mar;78(4):308-317. doi: 10.1002/pros.23476. Epub 2018 Jan 5.

PMID:
29314097
18.

Discovering cancer vulnerabilities using high-throughput micro-RNA screening.

Nikolic I, Elsworth B, Dodson E, Wu SZ, Gould CM, Mestdagh P, Marshall GM, Horvath LG, Simpson KJ, Swarbrick A.

Nucleic Acids Res. 2017 Dec 15;45(22):12657-12670. doi: 10.1093/nar/gkx1072.

19.

Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer.

Kalsbeek AMF, Chan EKF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Prostate. 2018 Jan;78(1):25-31. doi: 10.1002/pros.23440. Epub 2017 Nov 14.

PMID:
29134670
20.

Acetylated histone variant H2A.Z is involved in the activation of neo-enhancers in prostate cancer.

Valdés-Mora F, Gould CM, Colino-Sanguino Y, Qu W, Song JZ, Taylor KM, Buske FA, Statham AL, Nair SS, Armstrong NJ, Kench JG, Lee KML, Horvath LG, Qiu M, Ilinykh A, Yeo-Teh NS, Gallego-Ortega D, Stirzaker C, Clark SJ.

Nat Commun. 2017 Nov 7;8(1):1346. doi: 10.1038/s41467-017-01393-8.

21.

The evolution of chemotherapy for the treatment of prostate cancer.

Quinn DI, Sandler HM, Horvath LG, Goldkorn A, Eastham JA.

Ann Oncol. 2017 Nov 1;28(11):2658-2669. doi: 10.1093/annonc/mdx348. Review.

PMID:
29045523
22.

A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer.

Lin HM, Mahon KL, Weir JM, Mundra PA, Spielman C, Briscoe K, Gurney H, Mallesara G, Marx G, Stockler MR, PRIMe Consortium, Parton RG, Hoy AJ, Daly RJ, Meikle PJ, Horvath LG.

Int J Cancer. 2017 Nov 15;141(10):2112-2120. doi: 10.1002/ijc.30903. Epub 2017 Aug 8.

23.

A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer.

Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG, Horvath LG.

Ann Oncol. 2017 Aug 1;28(8):1903-1909. doi: 10.1093/annonc/mdx247.

PMID:
28486686
24.

Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up.

Grogan J, Gupta R, Mahon KL, Stricker PD, Haynes AM, Delprado W, Turner J, Horvath LG, Kench JG.

BJU Int. 2017 Nov;120(5):651-658. doi: 10.1111/bju.13857. Epub 2017 Apr 30.

25.

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.

Lin HM, Mahon KL, Spielman C, Gurney H, Mallesara G, Stockler MR, Bastick P, Briscoe K, Marx G, Swarbrick A, Horvath LG.

Br J Cancer. 2017 Apr 11;116(8):1002-1011. doi: 10.1038/bjc.2017.50. Epub 2017 Mar 9.

26.

Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer.

Bruce HM, Stricker PD, Gupta R, Savdie RR, Haynes AM, Mahon KL, Lin HM, Kench JG, Horvath LG.

Prostate. 2016 Dec;76(16):1491-1500. doi: 10.1002/pros.23233. Epub 2016 Jul 30.

PMID:
27473574
27.

Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.

Kalsbeek AM, Chan EF, Grogan J, Petersen DC, Jaratlerdsiri W, Gupta R, Lyons RJ, Haynes AM, Horvath LG, Kench JG, Stricker PD, Hayes VM.

Aging (Albany NY). 2016 Oct 5;8(11):2702-2712. doi: 10.18632/aging.101044.

28.

EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.

Barnet MB, O'Toole S, Horvath LG, Selinger C, Yu B, Ng CC, Boyer M, Cooper WA, Kao S.

J Thorac Oncol. 2017 Mar;12(3):585-590. doi: 10.1016/j.jtho.2016.09.001. Epub 2016 Sep 14.

29.

Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse.

Lomax AJ, Beith J, Bhadri V, Boyer M, Grimison P, Horvath LG, Kao S, Tattersall M, Thomas D, McNeil C.

Intern Med J. 2016 Dec;46(12):1392-1398. doi: 10.1111/imj.13232.

PMID:
27554283
30.

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, Vukovic P, Munster DJ, Nagasaki T, Barnard RT, Mahler SM, Anguille SA, Berneman Z, Horvath LG, Bradstock KF, Joshua DE, Clark GJ, Hart DN.

Oncoimmunology. 2016 May 5;5(6):e1168555. doi: 10.1080/2162402X.2016.1168555. eCollection 2016 Jun.

31.

Resolution of Novel Pancreatic Ductal Adenocarcinoma Subtypes by Global Phosphotyrosine Profiling.

Humphrey ES, Su SP, Nagrial AM, Hochgräfe F, Pajic M, Lehrbach GM, Parton RG, Yap AS, Horvath LG, Chang DK, Biankin AV, Wu J, Daly RJ.

Mol Cell Proteomics. 2016 Aug;15(8):2671-85. doi: 10.1074/mcp.M116.058313. Epub 2016 Jun 3.

32.

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials.

Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D.

Crit Rev Oncol Hematol. 2015 Dec;96(3):483-97. doi: 10.1016/j.critrevonc.2015.07.007. Epub 2015 Jul 26. Review.

PMID:
26481952
33.

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.

Lung Cancer. 2015 Aug;89(2):181-8. doi: 10.1016/j.lungcan.2015.05.007. Epub 2015 May 18.

PMID:
26024796
34.

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG.

Br J Cancer. 2015 Apr 14;112(8):1340-8. doi: 10.1038/bjc.2015.74. Epub 2015 Mar 31.

35.

ERG induces taxane resistance in castration-resistant prostate cancer.

Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS.

Nat Commun. 2014 Nov 25;5:5548. doi: 10.1038/ncomms6548.

36.

FAK signaling in human cancer as a target for therapeutics.

Lee BY, Timpson P, Horvath LG, Daly RJ.

Pharmacol Ther. 2015 Feb;146:132-49. doi: 10.1016/j.pharmthera.2014.10.001. Epub 2014 Oct 12. Review.

PMID:
25316657
37.

INPP4B is highly expressed in prostate intermediate cells and its loss of expression in prostate carcinoma predicts for recurrence and poor long term survival.

Rynkiewicz NK, Fedele CG, Chiam K, Gupta R, Kench JG, Ooms LM, McLean CA, Giles GG, Horvath LG, Mitchell CA.

Prostate. 2015 Jan;75(1):92-102. doi: 10.1002/pros.22895. Epub 2014 Oct 4.

PMID:
25284366
38.

Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.

Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG, Clark SJ; PRIMe consortium.

Br J Cancer. 2014 Oct 28;111(9):1802-9. doi: 10.1038/bjc.2014.463. Epub 2014 Aug 21.

39.

Extraprostatic extension (EPE) of prostatic carcinoma: is its proximity to the surgical margin or Gleason score important?

Gupta R, O'Connell R, Haynes AM, Stricker PD, Barrett W, Turner JJ, Delprado W, Horvath LG, Kench JG.

BJU Int. 2015 Sep;116(3):343-50. doi: 10.1111/bju.12911. Epub 2014 Dec 15.

40.

Expression of phosphorylated-mTOR during the development of prostate cancer.

Sutherland SI, Pe Benito R, Henshall SM, Horvath LG, Kench JG.

Prostate. 2014 Sep;74(12):1231-9. doi: 10.1002/pros.22840. Epub 2014 Jul 7.

PMID:
25043667
41.

Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.

Lin HM, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ, Horvath LG.

Br J Cancer. 2014 May 13;110(10):2462-71. doi: 10.1038/bjc.2014.181. Epub 2014 Apr 8.

42.

Phosphorylated Akt expression is a prognostic marker in early-stage non-small cell lung cancer.

Yip PY, Cooper WA, Kohonen-Corish MR, Lin BP, McCaughan BC, Boyer MJ, Kench JG, Horvath LG.

J Clin Pathol. 2014 Apr;67(4):333-40. doi: 10.1136/jclinpath-2013-201870. Epub 2013 Nov 21.

PMID:
24265323
43.

Adjuvant chemotherapy in elderly patients with pancreatic cancer.

Nagrial AM, Chang DK, Nguyen NQ, Johns AL, Chantrill LA, Humphris JL, Chin VT, Samra JS, Gill AJ, Pajic M; Australian Pancreatic Cancer Genome Initiative, Pinese M, Colvin EK, Scarlett CJ, Chou A, Kench JG, Sutherland RL, Horvath LG, Biankin AV.

Br J Cancer. 2014 Jan 21;110(2):313-9. doi: 10.1038/bjc.2013.722. Epub 2013 Nov 21.

44.

Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.

Lee BY, Hochgräfe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG, Daly RJ.

Mol Cancer Ther. 2014 Jan;13(1):190-201. doi: 10.1158/1535-7163.MCT-13-0225-T. Epub 2013 Nov 5.

45.

Circulating microRNAs predict biochemical recurrence in prostate cancer patients.

Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD.

Br J Cancer. 2013 Aug 6;109(3):641-50. doi: 10.1038/bjc.2013.369. Epub 2013 Jul 11.

46.

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.

Cooper WA, Yu B, Yip PY, Ng CC, Lum T, Farzin M, Trent RJ, Mercorella B, Clarkson A, Kohonen-Corish MR, Horvath LG, Kench JG, McCaughan B, Gill AJ, O'Toole SA.

J Clin Pathol. 2013 Sep;66(9):744-8. doi: 10.1136/jclinpath-2013-201607. Epub 2013 Jun 11.

PMID:
23757037
47.

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

Selinger CI, Rogers TM, Russell PA, O'Toole S, Yip P, Wright GM, Wainer Z, Horvath LG, Boyer M, McCaughan B, Kohonen-Corish MR, Fox S, Cooper WA, Solomon B.

Mod Pathol. 2013 Dec;26(12):1545-53. doi: 10.1038/modpathol.2013.87. Epub 2013 Jun 7.

48.

Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma.

Yip PY, Yu B, Cooper WA, Selinger CI, Ng CC, Kennedy CW, Kohonen-Corish MR, McCaughan BC, Trent RJ, Boyer MJ, Kench JG, Horvath LG, O'Toole SA.

J Thorac Oncol. 2013 Apr;8(4):408-14. doi: 10.1097/JTO.0b013e318283558e.

49.

Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer.

Hulf T, Sibbritt T, Wiklund ED, Patterson K, Song JZ, Stirzaker C, Qu W, Nair S, Horvath LG, Armstrong NJ, Kench JG, Sutherland RL, Clark SJ.

Oncogene. 2013 Jun 6;32(23):2891-9. doi: 10.1038/onc.2012.300. Epub 2012 Aug 6.

PMID:
22869146
50.

Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review.

Femia G, Hardy TA, Spies JM, Horvath LG.

Asia Pac J Clin Oncol. 2012 Jun;8(2):115-22. doi: 10.1111/j.1743-7563.2012.01544.x. Review.

PMID:
22524570

Supplemental Content

Loading ...
Support Center